Literature DB >> 1564338

A thymosin beta 4 ELISA using an antibody against the N terminal fragment thymosin beta 4 [1-14].

E Livaniou1, M Mihelic, G P Evangelatos, A Haritos, W Voelter.   

Abstract

A thymosin beta 4 ELISA was developed in which thymosin beta 4, absorbed on microwells, competed with thymosin beta 4 in solution for the binding sites of an anti-thymosin beta 4 antibody. The antibody molecules finally immobilized on the microwells were detected using a goat anti-rabbit immunoglobulin/horseradish peroxidase conjugate in combination with the substrate 2,2'-azino-bis-(3-ethylbenzthiazoline-6-sulfonic acid) diammonium salt, and measuring the relevant optical density values. Anti-thymosin beta 4 antibodies were raised in rabbits against intact thymosin beta 4 as well as against selected fragments of the peptide, i.e., the N terminal fragments thymosin beta 4[1-14] and thymosin beta 4[1-11]. The antibody against thymosin beta 4[1-14] was used in the thymosin beta 4 ELISA, because it showed minimal cross-reactivity (0.1%) with the highly homologous peptide thymosin beta 9 as well as exhibiting the highest titre. The ELISA procedure developed, apart from showing a minimal cross-reaction with thymosin beta 9, was fast, easy to perform and exhibited good assay characteristics.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1564338     DOI: 10.1016/0022-1759(92)90152-j

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  3 in total

1.  Distribution and biological activity ofβ-thymosins.

Authors:  M Mihelić; W Voelter
Journal:  Amino Acids       Date:  1994-02       Impact factor: 3.520

2.  Patients with cancer holding their own records: a randomised controlled trial.

Authors:  M Drury; P Yudkin; J Harcourt; R Fitzpatrick; L Jones; C Alcock; M Minton
Journal:  Br J Gen Pract       Date:  2000-02       Impact factor: 5.386

3.  Immunocytological and preliminary immunohistochemical studies of prothymosin alpha, a human cancer-associated polypeptide, with a well-characterized polyclonal antibody.

Authors:  Persefoni Klimentzou; Angeliki Drougou; Birgit Fehrenbacher; Martin Schaller; Wolfgang Voelter; Calypso Barbatis; Maria Paravatou-Petsotas; Evangelia Livaniou
Journal:  J Histochem Cytochem       Date:  2008-08-18       Impact factor: 2.479

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.